文献速递肝胆胰外科急腹症与外科感染

BCLC A期破裂性肝细胞癌:TACE与肝切除术预后比较的倾向性评分匹配里程碑分析

Comparison of the prognosis of BCLC stage A ruptured hepatocellular carcinoma patients after undergoing transarterial chemoembolization (TACE) or hepatectomy: a propensity score-matched landmark analysis.
PubMed 文献 · Surg Endosc · 2022-08-03

本研究纳入283例破裂性肝细胞癌患者,其中肝切除术175例、TACE 108例,经倾向性评分匹配(PSM)后各88对。匹配后肝切除术组1、3、5年总生存率分别为73.4%、45.4%、33.9%,TACE组为58.5%、40.6%、23.2%;1年内肝切除术预后优于TACE(P=0.022),但长期生存无差异(P=0.936)。

要点

  • PSM后肝切除术组1年内生存优于TACE组(P=0.022)。
  • 两组长期生存无统计学差异(P=0.936)。
  • 超出米兰标准者肝切除术生存优于TACE(P=0.043)。

核心结论

  • 破裂性肝细胞癌患者肝切除术的短期预后优于TACE,但长期预后无差异。

研究设计与样本

  • 回顾性队列研究,纳入283例破裂性HCC患者,肝切除术175例、TACE 108例,PSM后88对。
  • 采用Kaplan-Meier法比较长期预后,Landmark法比较PSM后短期与长期预后。

主要发现

  • PSM后肝切除术组1、3、5年OS率分别为73.4%、45.4%、33.9%,TACE组为58.5%、40.6%、23.2%。
  • 1年内肝切除术组预后优于TACE组(P=0.022),长期生存无差异(P=0.936)。
  • 符合米兰标准亚组两组生存无统计学差异(P=0.294),HR=1.56(0.68-3.59)。
  • 超出米兰标准亚组肝切除术组生存时间28.0个月(20.0-34.0),TACE组18个月(9.8-26.2),差异有统计学意义(P=0.043),HR=1.57(1.01-2.43)。

临床怎么用

  • 对于破裂性BCLC A期HCC,肝切除术可能改善短期生存,尤其对超出米兰标准者。
  • 符合米兰标准者两种治疗长期生存相似,选择需个体化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: At present, the choice of treatment modalities for ruptured hepatocellular carcinoma patients in BCLC stage A remains controversial, and this study compared the overall survival of ruptured HCC patients undergoing TACE or hepatectomy. METHODS: A total of 283 ruptured HCC patients treated at our liver surgery center were included in our study, of which 175 were treated with hepatectomy and 108 were treated with TACE. To reduce selection bias, we used a propensity score matching (PSM) model, which yielded a total of 88 pairs of patients. We used the Kaplan-Meier method to compare the long-term prognosis, and the Landmark method was used to compare the short-term and long-term prognoses of patients after PSM. Finally, we performed subgroup analysis according to whether it met the Milan criteria. RESULTS: After PSM, in the hepatectomy group, the 1-, 3-, and 5 year OS rates were 73.4%, 45.4%, and 33.9%, respectively. In the TACE group, the 1-, 3-, and 5 year OS rates were 58.5%, 40.6%, and 23.2%, respectively. Within one year, the hepatectomy group had a better prognosis than the TACE group (P = 0.022), but there was no difference in long-term survival(P = 0.936). In the subgroup analysis, in patients who met the Milan criteria, the survival curve indicated that there was no statistically significant difference in the survival prognosis between the two groups (P = 0.294) HR = 1.56(0.68-3.59); in the patients beyond the Milan criteria, the survival time was 28.0 months (20.0-34.0) in patients who underwent hepatectomy and 18 months (9.8-26.2) in patients who underwent TACE, and the survival curve indicated a statistically significant difference (P = 0.043) HR = 1.57(1.01-2.43). CONCLUSION: Our propensity score-matched study found that ruptured HCC patients treated by hepatectomy had a better short-term prognosis than those treated by TACE, but there was no difference in the long-term prognosis between the two treatment groups.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Xia F, Zhang Q, Chen X, et al. Comparison of the prognosis of BCLC stage A ruptured hepatocellular carcinoma patients after undergoing transarterial chemoembolization (TACE) or hepatectomy: a propensity score-matched landmark analysis. Surg Endosc. 2022. PMID: 35920912. doi:10.1007/s00464-022-09351-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。